Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel
01 Novembro 2021 - 8:00AM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced two recent senior
management appointments: Marc Rudoltz, M.D., as Chief Medical
Officer, and Doug Barry, J.D., as General Counsel.
“Marc‘s deep experience in oncology-clinical development, and
particular focus on targeted therapy, will be of great benefit as
Tango advances into the clinic in the first half of 2022 with
TNG908, our MTA-cooperative PRMT5 inhibitor,” said Barbara Weber,
M.D., president and Chief Executive Officer of Tango Therapeutics.
“I’m equally excited to have Doug joining our team, as his insights
and experience in the pharmaceutical and healthcare industry will
be invaluable as we continue our growth trajectory as a public
company.”
Dr. Rudoltz has more than 20 years' experience leading all
phases of clinical drug development. As the principal of MSR
Healthcare Consultants LLC, Dr. Rudoltz served as Chief Medical
Officer for a number of companies including Deciphera
Pharmaceuticals, and Constellation Pharmaceuticals and as a
clinical consultant for Blueprint Medicines. In these roles, Dr.
Rudoltz led teams to start and accelerate the clinical development
of a number of targeted small molecule anti-cancer agents including
Qinlock®, Aykavit®, Gavreto®, and pelabrisib. Previously, he worked
in clinical development roles for several companies, including
Novartis where he played key roles in the development and
commercialization of Gleevec® and Tasigna®. Dr. Rudoltz obtained
his B.S. in Chemical Biology from the Massachusetts Institute of
Technology and M.D. from SUNY-Upstate Medical University. He
completed residency training in Radiation Oncology at Thomas
Jefferson University followed by fellowship training in Cancer
Biology at the University of Pennsylvania. Dr. Rudoltz is the
author of 25 peer-reviewed publications.
Mr. Barry has been practicing law for over 20 years, and joins
Tango from Alexion Pharmaceuticals, where he was Vice President of
Corporate Law, and was responsible for public reporting, corporate
governance, financing transactions, and litigation. Prior to
Alexion, he was Associate General Counsel at Alere Inc., which was
acquired by Abbott Laboratories. Earlier in his career, Mr. Barry
spent 10 years as an attorney in the corporate department at Wilmer
Cutler Pickering Hale and Dorr LLP. Mr. Barry has a B.A. degree in
Political Science from Hobart College, a Master’s degree from
University of Virginia in International Relations and a juris
doctor from Northwestern University School of Law.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be considered
forward-looking statements. Forward-looking statements generally
relate to future events, Tango’s future operating performance,
goals, expectations, beliefs and development objectives for Tango’s
product pipeline. In some cases, you can identify forward-looking
statements by terminology such as “may”, “should”, “expect”,
“intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these
terms or variations of them or similar terminology. For example,
statements concerning the following include or constitute
forward-looking statements: Dr. Rudoltz experience will be of great
benefit to the Company as it advances TNG908 into clinical trials
in the first half of 2022 and the Company will continue its growth
trajectory as a public company. Such forward-looking statements are
subject to risks, uncertainties, and other factors which could
cause actual results to differ materially from those expressed or
implied by such forward looking statements. These forward-looking
statements are based upon estimates and assumptions that, while
considered reasonable by Tango and its management are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: Tango has a limited operating history and has not generated any
revenue to date from drug sales, and may never become profitable;
Tango will need to raise capital in the future and if we are unable
to raise capital when needed or on attractive terms, we would be
forced to delay, scale back or discontinue some of our development
programs or future commercialization efforts; we may be unable to
advance our preclinical development programs into and through the
clinic for safety or efficacy reasons or commercialize our product
candidates or we may experience significant delays in doing so as a
result of factors beyond Tango’s control; Tango’s approach to the
discovery and development of product candidates is novel and
unproven, which makes it difficult to predict the time, cost of
development, and likelihood of successfully developing any
products; Tango may not identify or discover additional product
candidates or may expend limited resources to pursue a particular
product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which
there is a greater likelihood of success; our products candidates
may cause adverse or other undesirable side effects that could,
among other things, delay or prevent regulatory approval; our
dependence on third parties for conducting clinical trials and
producing drug product; our ability to obtain and maintain patent
and other intellectual property protection for our technology and
product candidates or the scope of intellectual property protection
obtained is not sufficiently broad; and delays and other impacts on
product development and clinical trials from the COVID-19 pandemic.
Additional information concerning risks, uncertainties and
assumptions can be found in Tango’s filings with the SEC,
including the risk factors referenced in Tango’s Current Report on
Form 8-K filed with the SEC on August 13, 2021. You should not
place undue reliance on forward-looking statements in this
presentation, which speak only as of the date they are made and are
qualified in their entirety by reference to the cautionary
statements herein. Tango specifically disclaims any duty to update
these forward-looking statements.
Investor Contact:Sam MartinArgot
Partnerstango@argotpartners.com
Media Contact:Joshua R. Mansbach Argot Partners
tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024